Erythropoietin (EPO) Market Report 2025

This Erythropoietin (EPO) market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The erythropoietin (EPO) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2024 to $19.25 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patient education and awareness, pharmaceutical industry consolidation, healthcare reimbursement policies, market expansion and demand growth, patent expiration and biosimilar entry.

The erythropoietin (EPO) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to market competition and biosimilar impact, disease prevalence projections, healthcare policy and reimbursement changes, emerging markets growth, clinical trials and research focus. Major trends in the forecast period include supply chain management, global expansion and emerging markets, patient education and awareness, reimbursement policies, market consolidation and mergers.

The increasing prevalence of chronic kidney diseases is expected to drive the demand for the erythropoietin market in the coming years. The rise in chronic kidney disease cases necessitates the administration of erythropoietin, which is used to stimulate the production of red blood cells and enhance immunity. For example, in 2023, the Centers for Disease Control, a U.S.-based federal agency, estimated that approximately 14% of U.S. adults - around 35.5 million individuals - suffer from chronic kidney disease (CKD). Thus, the growing incidence of chronic kidney diseases is boosting the demand for erythropoietin, subsequently increasing market revenues.

The rising incidence of hematologic cancer is projected to drive the growth of the erythropoietin market in the future. Hematologic cancer refers to a category of cancers that originate in the blood and impact the blood, bone marrow, and lymphatic system, including diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a crucial role in managing cancer-related anemia by stimulating the production of red blood cells, which helps alleviate anemia in cancer patients, especially those undergoing chemotherapy. For instance, in 2023, the American Cancer Society, a U.S.-based voluntary health organization dedicated to eliminating cancer, estimated that leukemia would affect 59,610 Americans and lead to 23,710 deaths. Additionally, new cases of non-Hodgkin lymphoma are expected to impact 80,550 individuals in the United States, resulting in 20,180 deaths. Therefore, the increasing prevalence of hematologic cancers is advancing the erythropoietin market.

Major companies in the erythropoietin market are concentrating on introducing oral medications that provide more convenient alternatives to traditional injectable therapies. This approach aims to enhance patient comfort, compliance, and treatment flexibility, particularly for individuals dealing with chronic conditions such as anemia in chronic kidney disease (CKD). For example, in February 2023, GlaxoSmithKline (GSK), a UK-based multinational pharmaceutical and biotechnology firm, launched Jesduvroq (daprodustat) tablets. This oral medication aids in increasing erythropoietin levels to help manage anemia in CKD patients by maintaining hemoglobin levels within a target range. The primary goal of Jesduvroq is to offer a more convenient alternative to injectable therapies, thereby improving patient comfort, compliance, and treatment flexibility for dialysis patients.

Major players in the erythropoietin market are innovating with products such as Varenzin-CA1 to solidify their market position. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA designed to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Elanco, a US-based pharmaceutical company, secured FDA approval for Varenzin-CA1 in May 2023. This breakthrough innovation for cats boasts a unique mode of action that triggers the genetic transcription of erythropoietin (EPO), leading to increased EPO and red blood cell production in a cat's body. Varenzin-CA1 sets a new standard of care for cats experiencing nonregenerative anemia due to CKD, offering convenience for at-home use.

Major companies operating in the erythropoietin (EPO) market include Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.

Erythropoietin (EPO) is a glycoprotein hormone naturally produced by the peritubular cells of the kidney, stimulating the production of red blood cells. It is utilized in the treatment of anemia, a condition characterized by a shortage of red blood cells. Symptoms of anemia, such as weakness, fatigue, and shortness of breath, arise due to the crucial role of red blood cells in delivering oxygen to tissues and organs.

The primary types of erythropoietin products include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin that is synthesized in cell culture. Erythropoietin falls into different drug classes, including biologics and biosimilars, and finds applications in various medical fields such as cancer, hematology, renal diseases, neurology, and others.

The erythropoietin (EPO) market research report is one of a series of new reports that provides erythropoietin (EPO) market statistics, including erythropoietin (EPO) industry global market size, regional shares, competitors with an erythropoietin (EPO) market share, detailed erythropoietin (EPO) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (EPO) industry. This erythropoietin (EPO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the erythropoietin (EPO) market in 2024. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.